Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Guardant Health Inc
(NQ:
GH
)
18.88
+0.30 (+1.61%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Guardant Health Inc
< Previous
1
2
3
4
5
Next >
Guardant Health Initiates ORACLE Study to Evaluate Performance of Guardant Reveal™ Blood Test to Predict Recurrence Across Early-Stage Cancers
October 05, 2021
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Showcases Data at ESMO 2021 Demonstrating Utility of Guardant360® Liquid Biopsy to Obtain Comprehensive Molecular Information to Guide Targeted Therapy Options for Late-Stage Cancers
September 15, 2021
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health to Participate in the UBS Genomics 2.0 and MedTech Innovations Summit
August 06, 2021
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Announces New Leadership Structure Aligned with Strategic Growth Objectives and Expands Board of Directors
August 05, 2021
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Reports Second Quarter 2021 Financial Results
August 05, 2021
From
Guardant Health, Inc.
Via
Business Wire
Fight Colorectal Cancer and Guardant Health Join Forces to Recognize Excellence in Overcoming Challenges to Colorectal Cancer Screening During Pandemic
July 20, 2021
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health to Report Second Quarter Financial Results on August 5, 2021
July 13, 2021
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Expands Guardant360® Portfolio With New Tests for Treatment Response Monitoring and Complete Genomic Profiling
June 22, 2021
From
Guardant Health, Inc.
Via
Business Wire
CORRECTING and REPLACING Study Shows Guardant Reveal™ Blood-Only Liquid Biopsy Test Predicts Risk for Colorectal Cancer Recurrence with Industry-Leading Sensitivity
June 18, 2021
From
Guardant Health
Via
Business Wire
CORRECTING and REPLACING Guardant Health Presents Data at 2021 ASCO Annual Meeting Showing Utility of Liquid Biopsy in Early- and Late-Stage Cancers
June 18, 2021
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Announces Appointment of Chris Freeman as Chief Commercial Officer
June 08, 2021
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Presents Data at 2021 ASCO Annual Meeting Showing Blood Test Highly Accurate in Detecting Colorectal Cancer in Patients With Early-Stage Cancer
June 04, 2021
From
Guardant Health, Inc.
Via
Business Wire
Guardant360® CDx Receives FDA Approval as First and Only Liquid Biopsy Companion Diagnostic for Amgen’s LUMAKRAS™ (sotorasib) KRASG12C Inhibitor for Use in Advanced Non-Small Cell Lung Cancer
May 28, 2021
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Files Lawsuit Against Natera for Misleading Oncologists
May 28, 2021
From
Guardant Health, Inc.
Via
Business Wire
Guardant360® CDx Receives FDA Approval as Companion Diagnostic for Janssen’s RYBREVANT™ (amivantamab-vmjw) for Use in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
May 21, 2021
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health to Participate in Upcoming June Investor Conferences
May 20, 2021
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Presents Data at 2021 ASCO Annual Meeting Showing Utility of Liquid Biopsy in Early- and Late-Stage Cancers
May 19, 2021
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Reports First Quarter 2021 Financial Results
May 06, 2021
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Appoints Craig Eagle, MD as Chief Medical Officer
May 03, 2021
From
Guardant Health, Inc.
Via
Business Wire
Study Shows Guardant Reveal™ Blood-Only Liquid Biopsy Test Predicts Risk for Colorectal Cancer Recurrence with Industry-Leading Sensitivity
April 30, 2021
From
Guardant Health
Via
Business Wire
Guardant Health to Participate in the BofA Securities 2021 Healthcare Conference
April 29, 2021
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Announces Collaboration With Daiichi Sankyo to Develop Guardant360® CDx as a Companion Diagnostic for Enhertu® in Advanced Metastatic Non-Small Cell Lung Cancer
April 27, 2021
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health to Report First Quarter Financial Results on May 6, 2021
April 12, 2021
From
Guardant Health, Inc.
Via
Business Wire
Data at AACR Demonstrate Growing Clinical Utility of Guardant Health Liquid Biopsies in the Treatment and Management of Advanced Cancers
April 10, 2021
From
Guardant Health, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.